The promise of new gene therapies to address unmet needs for the treatment of rare and complex diseases is driving increased demand for research into viral vector-based therapeutics. Whether your key therapeudic strategy is based on mRNA, adenoviruses (AV), adeno-associated viruses (AAV), or lentiviruses (LV), our genetic analysis tools are aimed at advancing scientific discoveries and increasing the efficiency of process development for safer and repeatable gene therapies.

 

LI1200x627

Compendial and non-compendial tests with qPCR and dPCR technologies for gene therapy development

Genetic technologies present vital tools in gene therapy development and product manufacturing. Within this infographic distinguish how qPRC and dPCR technologies can benefit characterization, in-process, and release assays for gene therapy development to expedite your therapy commercialization.

View infographic ›

Genetic analysis technologies enable efficient mRNA vaccine development and manufacturing

Gennova Biopharmaceuticals, an India-based company, develops the first thermostable mRNA vaccine to protect the region against COVID-19.  Analytics for vaccine development are critical in both GMP and non-GMP settings, and Gennova Biopharmaceuticals applies an orthogonal approach to test the quality of their product with Sanger sequencing, qPCR, and digital PCR.  Sanger sequencing is used for identity testing and mRNA batch release, while qPRC methods test and identify product impurities.  To determine the concentration of the mRNA product, digital PCR method is employed.  Watch the video to learn more.  

Contact a sales specialist about our genetic analysis technologies products.

delivery-vector

Proof of concept
 

Accelerate your gene therapy investigation by incorporating genetic analysis from the beginning of the therapeutic gene development workflow to identify target lesions, design transgene vectors, develop animal models, and identify potential predictive biomarkers.

proof-concept

Delivery vector design and optimization

Accelerate time to therapeutic viral vector production by using sensitive, specific, fast, and efficient genetic technologies to design viral vectors that are optimized to maximize transfection, transgene expression, and safety.
 

vehicle-product

Delivery vehicle production
 

Streamline your vector delivery vehicle production with accurately optimized transgene dosage, highly specific host cell authentication, and precise quantitation of in-process and adventitious contaminants.

 

preclinical-dev

Preclinical development
 

Maximize the value of your preclinical investigations using genetic analyses early in the preclinical development process to reveal valuable insights into dosing, therapeutic efficacy, toxicology, and transfection efficiency.
 

Resources

Genetic analysis technologies

Learn how our comprehensive genetic portfolio including microarray, sanger sequencing, next-generation sequencing, dPCR, and qPCR solutions, enables reliable insights throughout the gene therapy product development workflow

Download solution guide ›

biopharma-scientist-on-portal

Viral titer dPCR solutions

Absolute Q Viral Titer dPCR assays enable easy and accurate quantification of viral vectors.

Learn more ›

biopharma-services

Biopharma service and support solutions

Discover innovative support and services specific for Biopharma. We can support you with remote tools, qualification services (IQ/OQ/PQ or IPV), computer system validation and OEM expertise.

Explore more ›

Style Sheet for Global Design System